title: Clinical experience with 1000 patients treated with cefetamet pivoxil.
abstract: Clinical studies have been carried out world-wide on cefetamet pivoxil, a new orally active cephalosporin. This paper reports on the first 1000 patients treated with the antibiotic; another 505 patients received standard antibiotics, mainly cefadroxil and cefaclor, for comparison. The results show that single doses of 1500 and 1200 mg cefetamet pivoxil were fully effective in gonorrhoea. Comparative trials in uncomplicated urinary tract infection indicate a significant superiority of a single dose of 2 g cefetamet pivoxil (n = 158; 90.0% cure) versus 2 g cefadrox (n = 162; 77.0% cure). In complicated urinary tract infections, a comparable outcome was achieved with a single daily dose of 2 g cefetamet pivoxil for 10 days (n = 99; 90% cure) and 1 g cefadroxil twice daily for 10 days (n = 98; 76.5% cure). The clinical response rate in acute exacerbation of chronic bronchitis was 89.4% in the group receiving cefetamet pivoxil (136 patients) and 83% in the cefaclor-treated group (n = 122). Treatment with 1000 or 2000 mg cefetamet pivoxil achieved a (bacteriological) success rate of 96% compared to 95% with cefaclor in acute ear, nose and throat-infections (n = 91). Overall, based on 894 isolated pathogens prior to therapy, the bacteriological response rate was 90% and it would appear that in vivo the spectrum of this cephalosporin covers a wide range of Gram-negative and Gram-positive pathogens, including urinary pathogens, but excluding Enterococci and Pseudomonas. Cefetamet pivoxil proved to be well tolerated. Mild to moderate adverse events were reported in 7.1% of patients but only 2 of the 1000 patients treated with cefetamet pivoxil were withdrawn because of diarrhoea, which subsided rapidly. There were no clinically relevant deviations in laboratory parameters.
authors.affiliation: Faculty of Medicine, University of Buenos Aires, Argentina.
authors.forename: L
authors.initials: L
authors.lastname: Bernstein-Hahn
authors.forename: E
authors.initials: E
authors.lastname: Valdés
authors.forename: P
authors.initials: P
authors.lastname: Gehanno
authors.forename: H
authors.initials: H
authors.lastname: Giamarellou
authors.forename: A
authors.initials: A
authors.lastname: Lassus
authors.forename: W T
authors.initials: WT
authors.lastname: Ulmer
authors.forename: N
authors.initials: N
authors.lastname: Vetter
authors.forename: F
authors.initials: F
authors.lastname: Walhor
authors.forename: R
authors.initials: R
authors.lastname: Wettengel
authors.forename: M
authors.initials: M
authors.lastname: Fernex
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000150:complications; D015296:Ceftizoxime / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy; D012107:Research Design; D014526:Urethritis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
chemical_list: D015296:Ceftizoxime; C047445:cefetamet pivoxyl